A subgroup analysis of the KEYNOTE-355 trial sought to determine which patients with metastatic TNBC would benefit from treatment with pembrolizumab and chemotherapy. Final results of the KEYNOTE-355 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results